Pathophysiology of Nonadvanced SM
Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 years.
Akin C, Sabato V, Gotlib J, et al. J Allergy Clin Immunol. 2026;158(2):421-431.
Mastocytosis.
Akin C, Arock M, Carter MC, et al. Nat Rev Dis Primers. 2025;11(1):30.
Tyrosine kinase inhibitors in non-advanced systemic mastocytosis.
Akin C. Immunol Allergy Clin N Am. 2023;43(4):743-750.
SOHO state of the art update and next questions: current and emerging therapies for systemic mastocytosis.
Chifotides HT, Bose P. Clin Lymphoma Myeloma Leuk. 2025;25(1):1-12.
Management of bone health in adult mastocytosis.
Degboé Y, Nezzar C, Alary P, et al. Curr Osteoporos Rep. 2025;23(1):10.
Avapritinib versus placebo in indolent systemic mastocytosis.
Gotlib J, Castells M, Elberink HO, et al. NEJM Evid. 2023;2(6):EVIDoa2200339.
Patient-reported outcomes among patients with systemic mastocytosis in routine clinical practice: results of the TouchStone SM patient survey.
Mesa RA, Sullivan EM, Dubinski D, et al. Cancer. 2022;128(20):3691-3699.
Systemic mastocytosis in adults: 2026 update on diagnosis, risk stratification and management.
Pardanani A. Am J Hematol. 2026;101(9):2371-2392.
Systemic mastocytosis: multidisciplinary approach.
Zanotti R, Tanasi I, Crosera L, et al. Mediterr J Hematol Infect Dis. 2021;13(1):e2021068.
Patient Videos
Indolent Systemic Mastocytosis (ISM): The Patient Experience
Listen to Barbara, Laura, and Mary Jane share their stories about being diagnosed and living with indolent SM.
Clinical Guidelines and Resources
Arber DA, Orazi A, Hasserjian R, et al. Blood. 2016;127(20):2391-2405.
Erratum: The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.
Arber DA, Orazi A, Hasserjian R, et al. Blood. 2016;127(20):2391-2405
The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms.
Khoury JD, Solary E, Abla O, et al. Leukemia. 2022;36(7):1703-1719.
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.
Arber DA, Orazi A, Hasserjian RP, et al. Blood. 2022;140(11):1200-1228.
NCCN® Clinical Practice Guidelines in Oncology®: Systemic Mastocytosis.
National Comprehensive Cancer Network.
Personalized management strategies in mast cell disorders: ECNM-AIM User’s Guide for Daily Clinical Practice.
Valent P, Hartmann K, Schwaab J, et al. J Allergy Clin Immunol Pract. 2022;10(8):1999-2012.e6.
Total Rise in Peripheral Tryptase After Systemic Event (TRIPTASE) Calculator
American Initiative in Mast Cell Diseases (AIM)
AIM is dedicated to advancing the research, education, and treatment of mastocytosis and related mast cell diseases.
The European Competence Network on Mastocytosis (ECNM)
The goal of the ECNM is to improve disease recognition, diagnosis, and therapy in patients with mastocytosis in Europe.
Patient Resources
The Mast Cell Disease Society, Inc. (TMS)
TMS is dedicated to providing multifaceted support to patients, families, and medical professionals in the community and to leading the advancement of knowledge and research in mast cell diseases through education, advocacy, and collaboration.
Genetic and Rare Diseases Information Center
GARD helps patients find information, services, experts, financial aid, and support groups.
National Organization for Rare Disorders (NORD)
NORD is a patient advocacy organization committed to the identification, treatment, and cure of rare disorders through programs of education, advocacy, research, and patient services.
NCCN® Guidelines for Patients®: Systemic Mastocytosis
National Comprehensive Cancer Network.
Systemic Mastocytosis in the Spotlight
Focusing on Diagnosis and Management of Nonadvanced SM
| Faculty: | Matthew P. Giannetti, MD ; Jeremy C. McMurray, MD; Cecelia Y. Arana Yi, MD |
| Release: | 11/15/2026 |
| Expiration: | 12/15/2026 |
